Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 143

Similar articles for PubMed (Select 22179664)

1.

Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.

Daud AI, Krishnamurthi SS, Saleh MN, Gitlitz BJ, Borad MJ, Gold PJ, Chiorean EG, Springett GM, Abbas R, Agarwal S, Bardy-Bouxin N, Hsyu PH, Leip E, Turnbull K, Zacharchuk C, Messersmith WA.

Clin Cancer Res. 2012 Feb 15;18(4):1092-100. doi: 10.1158/1078-0432.CCR-11-2378. Epub 2011 Dec 16.

2.

Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.

Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I.

Oncologist. 2014 Apr;19(4):346-7. doi: 10.1634/theoncologist.2014-0022. Epub 2014 Mar 27.

3.

Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.

Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I.

Oncologist. 2014 Apr;19(4):348-9. doi: 10.1634/theoncologist.2014-0021. Epub 2014 Mar 27.

4.

Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study.

Isakoff SJ, Wang D, Campone M, Calles A, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Calvo E.

Br J Cancer. 2014 Nov 25;111(11):2058-66. doi: 10.1038/bjc.2014.508. Epub 2014 Oct 7.

5.

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.

Cortes JE, Kantarjian HM, Brümmendorf TH, Kim DW, Turkina AG, Shen ZX, Pasquini R, Khoury HJ, Arkin S, Volkert A, Besson N, Abbas R, Wang J, Leip E, Gambacorti-Passerini C.

Blood. 2011 Oct 27;118(17):4567-76. doi: 10.1182/blood-2011-05-355594. Epub 2011 Aug 24. Erratum in: Blood. 2013 Oct 3;122(14):2524.

6.

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.

Brümmendorf TH, Cortes JE, de Souza CA, Guilhot F, Duvillié L, Pavlov D, Gogat K, Countouriotis AM, Gambacorti-Passerini C.

Br J Haematol. 2015 Jan;168(1):69-81. doi: 10.1111/bjh.13108. Epub 2014 Sep 8.

7.

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.

Gambacorti-Passerini C, Brümmendorf TH, Kim DW, Turkina AG, Masszi T, Assouline S, Durrant S, Kantarjian HM, Khoury HJ, Zaritskey A, Shen ZX, Jin J, Vellenga E, Pasquini R, Mathews V, Cervantes F, Besson N, Turnbull K, Leip E, Kelly V, Cortes JE.

Am J Hematol. 2014 Jul;89(7):732-42. doi: 10.1002/ajh.23728. Epub 2014 Apr 28.

8.

Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy.

Campone M, Bondarenko I, Brincat S, Hotko Y, Munster PN, Chmielowska E, Fumoleau P, Ward R, Bardy-Bouxin N, Leip E, Turnbull K, Zacharchuk C, Epstein RJ.

Ann Oncol. 2012 Mar;23(3):610-7. doi: 10.1093/annonc/mdr261. Epub 2011 Jun 23.

9.

A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.

Abbas R, Hug BA, Leister C, Gaaloul ME, Chalon S, Sonnichsen D.

Cancer Chemother Pharmacol. 2012 Jan;69(1):221-7. doi: 10.1007/s00280-011-1688-7. Epub 2011 Jun 21.

PMID:
21691746
10.

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.

Kantarjian HM, Cortes JE, Kim DW, Khoury HJ, Brümmendorf TH, Porkka K, Martinelli G, Durrant S, Leip E, Kelly V, Turnbull K, Besson N, Gambacorti-Passerini C.

Blood. 2014 Feb 27;123(9):1309-18. doi: 10.1182/blood-2013-07-513937. Epub 2013 Dec 17. Erratum in: Blood. 2014 Aug 7;124(6):981.

11.

Bosutinib: a novel second-generation tyrosine kinase inhibitor.

Isfort S, Keller-v Amsberg G, Schafhausen P, Koschmieder S, Brümmendorf TH.

Recent Results Cancer Res. 2014;201:81-97. doi: 10.1007/978-3-642-54490-3_4. Review.

PMID:
24756786
12.

Bosutinib treatment for Philadelphia chromosome-positive leukemias.

Bethelmie-Bryan B, Lord K, Holloway S, Khoury HJ.

Future Oncol. 2014 Feb;10(2):179-85. doi: 10.2217/fon.13.268.

PMID:
24490604
13.

A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects.

Abbas R, Leister C, Sonnichsen D.

Clin Drug Investig. 2013 Aug;33(8):589-95. doi: 10.1007/s40261-013-0103-z.

PMID:
23839484
14.

Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia.

Hsyu PH, Mould DR, Upton RN, Amantea M.

Cancer Chemother Pharmacol. 2013 Jan;71(1):209-18. doi: 10.1007/s00280-012-1998-4. Epub 2012 Oct 16. Erratum in: Cancer Chemother Pharmacol. 2013 Apr;71(4):1105-6.

PMID:
23070145
15.

Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.

Abbas R, Leister C, El Gaaloul M, Chalon S, Sonnichsen D.

Clin Ther. 2012 Sep;34(9):2011-9.e1. doi: 10.1016/j.clinthera.2012.07.006. Epub 2012 Aug 9.

PMID:
22884766
16.

A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.

Wong KK, Fracasso PM, Bukowski RM, Lynch TJ, Munster PN, Shapiro GI, Jänne PA, Eder JP, Naughton MJ, Ellis MJ, Jones SF, Mekhail T, Zacharchuk C, Vermette J, Abbas R, Quinn S, Powell C, Burris HA.

Clin Cancer Res. 2009 Apr 1;15(7):2552-8. doi: 10.1158/1078-0432.CCR-08-1978. Epub 2009 Mar 24.

17.

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.

Cortes JE, Kim DW, Kantarjian HM, Brümmendorf TH, Dyagil I, Griskevicius L, Malhotra H, Powell C, Gogat K, Countouriotis AM, Gambacorti-Passerini C.

J Clin Oncol. 2012 Oct 1;30(28):3486-92. Epub 2012 Sep 4.

18.

Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.

Stansfield L, Hughes TE, Walsh-Chocolaad TL.

Ann Pharmacother. 2013 Dec;47(12):1703-11. doi: 10.1177/1060028013503124. Review.

PMID:
24396109
19.

Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia.

Keller G, Schafhausen P, Brummendorf TH.

Expert Rev Hematol. 2009 Oct;2(5):489-97. doi: 10.1586/ehm.09.42. Review.

PMID:
21083014
20.

Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.

Infante JR, Camidge DR, Mileshkin LR, Chen EX, Hicks RJ, Rischin D, Fingert H, Pierce KJ, Xu H, Roberts WG, Shreeve SM, Burris HA, Siu LL.

J Clin Oncol. 2012 May 1;30(13):1527-33. doi: 10.1200/JCO.2011.38.9346. Epub 2012 Mar 26.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk